Program
empagliflozin
Also written as “BI 10773”, “Empagliflozin” and “BI10773”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.
Drug pageEmpagliflozin: every studyMany companies study it; this page follows only the 124 they lead. All 404 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 992 open or running | phase 4since Oct 27, 2015 | Nov 14, 2007 | Dec 11, 2026phase 1 · NCT07845630 |
| ADIUMits history only | 40 open or running | no phasesince Mar 9, 2026 | Mar 9, 2026 | none ahead |
| Getz Pharmaits history only | 41 open or running | phase 4since Nov 27, 2020 | Nov 27, 2020 | Dec 31, 2026phase 4 · NCT05164263 |
| Gedeon Richter Plc.its history only | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 21 open or running | phase 4since Jan 15, 2026 | Aug 1, 2016 | Aug 2027phase 4 · NCT07365358 |
| Dong Wha Pharmaceuticalits history only | 20 open or running | phase 1since Apr 10, 2023 | Apr 10, 2023 | none ahead |
| Kobe Universityits history only | 20 open or running | phase 3since Jul 10, 2019 | Jul 10, 2019 | none ahead |
| Celltrionits history only | 11 open or running | phase 3since Jun 30, 2025 | Jun 30, 2025 | Dec 2026phase 3 · NCT07093476 |
| Dong-A STits history only | 10 open or running | phase 1since Dec 5, 2018 | Dec 5, 2018 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| Hyundai Pharmits history only | 11 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 3since Feb 9, 2017 | Feb 9, 2017 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| Pharma Nuevaits history only | 11 open or running | phase 1since Mar 6, 2024 | Mar 6, 2024 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 4since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 24, 2013.
- Jul 10, 2018Phase 3 study in Renal Insufficiency, ChronicNCT03594110 · 6,609 enrolled · United States, Canada, China and more
- Aug 9, 2018Phase 1 study in HealthyNCT03629054 · 30 enrolled · Germany
- Nov 4, 2019Phase 3 study in Heart FailureNCT04157751 · 530 enrolled · United States, Belgium, Canada and more
- Jan 16, 2020Phase 3 study in Diabetes Mellitus, Type 2NCT04233801 · 219 enrolled · China
- Aug 10, 2020Phase 3 study in Myocardial InfarctionNCT04509674 · 6,522 enrolled · United States, Argentina, Australia and more
- Aug 26, 2020Phase 4 study in Diabetes Mellitus, Type 2NCT04531462 · 129 enrolled · Japan
- Oct 6, 2021Phase 1 study in HealthyNCT05083949 · 32 enrolled · Brazil
- Jan 5, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05182840 · 714 enrolled · United States, Argentina, Australia and more
- Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06926660 · 492 enrolled · United States, Argentina, Australia and more
- Apr 30, 2025Phase 1 study in HealthyNCT06962826 · 14 enrolled · Germany
- Jun 17, 2025Phase 1 study in HealthyNCT07035457 · 15 enrolled · Germany
- Aug 5, 2025Phase 3 study in Renal Insufficiency, ChronicNCT07107945 · 135 enrolled · United States, Argentina, Australia and more
- Aug 19, 2025Phase 1 study in HealthyNCT07133399 · 32 enrolled · Germany
- Sep 23, 2026Phase 1 study in HealthyNCT07845630 · 36 planned · Germany
Ahead
- Dec 11, 2026Primary completion: phase 1 study in HealthyNCT07845630
- Apr 16, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07107945
TargetBeta
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 99 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07845630Healthy · Germany | 1 | Recruiting | Dec 11, 2026 | 36 |
| NCT07133399Healthy · Germany | 1 | Completed | Oct 22, 2025 | 32 |
| NCT07107945Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 16, 2027 | 135 |
| NCT07035457Healthy · Germany | 1 | Completed | Aug 7, 2025 | 15 |
| NCT06962826Healthy · Germany | 1 | Completed | Jun 26, 2025 | 14 |
| NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Aug 14, 2026 | 492 |
| NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Jun 19, 2023 | 714 |
| NCT05083949Healthy · Brazil | 1 | Completed | Aug 6, 2021 | 32 |
| NCT04531462Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Aug 19, 2022 | 129 |
| NCT04509674Myocardial Infarction · United States, Argentina, Australia and more | 3 | Completed | Nov 5, 2023 | 6,522 |
| NCT04233801Diabetes Mellitus, Type 2 · China | 3 | Completed | Mar 3, 2022 | 219 |
| NCT04157751Heart Failure · United States, Belgium, Canada and more | 3 | Completed | May 28, 2021 | 530 |
| NCT03629054Healthy · Germany | 1 | Completed | Nov 5, 2018 | 30 |
| NCT03594110Renal Insufficiency, Chronic · United States, Canada, China and more | 3 | Completed | Jul 5, 2022 | 6,609 |
| NCT03448419Heart Failure · United States, Australia, Canada and more | 3 | Completed | Sep 30, 2019 | 312 |
| NCT03448406Heart Failure · United States, Australia, Canada and more | 3 | Completed | Oct 4, 2019 | 315 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Oct 19, 2022 | 175 |
| NCT03332212Heart Failure · United Kingdom | 3 | Completed | May 21, 2020 | 72 |
| NCT03259490Healthy · Germany | 1 | Completed | Nov 13, 2017 | 30 |
| NCT03057977Heart Failure · United States, Argentina, Australia and more | 3 | Completed | May 1, 2020 | 3,730 |
| NCT03057951Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Apr 26, 2021 | 5,988 |
| NCT02821910Healthy · Germany | 1 | Completed | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Oct 5, 2016 | 22 |
| NCT02782624Healthy · Germany | 1 | Completed | Nov 2009 | 16 |
| NCT02758171Healthy · Germany | 1 | Completed | Jul 29, 2016 | 56 |
| NCT02702011Diabetes Mellitus, Type 1 · Japan | 2 | Completed | Sep 5, 2016 | 48 |
| NCT02632747Diabetes Mellitus, Type 1 · Canada | 2 | Completed | Dec 19, 2017 | 31 |
| NCT02589639Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Apr 18, 2017 | 269 |
| NCT02589626Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Jun 2, 2017 | 65 |
| NCT02580591Diabetes Mellitus, Type 1 · United States, Australia, Canada and more | 3 | Completed | Sep 12, 2017 | 977 |
| NCT02577315Healthy · Russian Federation | 1 | Completed | Oct 2015 | 25 |
| NCT02489968Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Nov 18, 2016 | 880 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Aug 26, 2016 | 275 |
| NCT02414958Diabetes Mellitus, Type 1 · United States, Australia, Austria and more | 3 | Completed | Apr 20, 2017 | 730 |
| NCT02276365Healthy | 1 | Completed | Jul 2009 | 20 |
| NCT02266472Healthy · Germany | 1 | Completed | Dec 2014 | 30 |
| NCT02230995Healthy · Germany | 1 | Completed | Oct 2014 | 30 |
| NCT02182830Diabetes Mellitus, Type 2 · United States | 3 | Completed | May 18, 2017 | 166 |
| NCT02182453Healthy | 1 | Completed | Aug 2008 | 48 |
| NCT02172274Healthy | 1 | Completed | Jul 2008 | 8 |
| NCT02172261Healthy | 1 | Completed | Jun 2009 | 16 |
| NCT02172248Healthy | 1 | Completed | Mar 2009 | 16 |
| NCT02172235Healthy | 1 | Completed | Jul 2010 | 20 |
| NCT02172222Healthy | 1 | Completed | Sep 2009 | 16 |
| NCT02172209Healthy | 1 | Completed | Feb 2008 | 14 |
| NCT02172196Healthy | 1 | Completed | Jul 2009 | 16 |
| NCT02172170Healthy | 1 | Completed | Mar 2007 | 72 |
| NCT02121483Diabetes Mellitus, Type 2 · United States, France, Israel and more | 1 | Completed | Feb 2016 | 27 |
| NCT02106923Healthy · United States | 1 | Completed | Jun 2014 | 72 |
| NCT02102932Healthy · China | 1 | Completed | Aug 2014 | 96 |
| NCT02028767Healthy · Canada | 1 | Completed | Feb 2014 | 32 |
| NCT01984606Diabetes Mellitus, Type 2 | 3 | Withdrawn | Feb 2017 | 0 |
| NCT01975220Healthy · United States | 1 | Completed | Dec 2013 | 72 |
| NCT01947855Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Dec 2013 | 60 |
| NCT01924767Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Nov 2007 | 48 |
| NCT01907113Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Dec 2009 | 40 |
| NCT01867307Diabetes Mellitus, Type 2 · United States | 2 | Completed | Oct 2015 | 39 |
| NCT01844531Healthy · Germany | 1 | Completed | Nov 2013 | 24 |
| NCT01811953Healthy · Germany | 1 | Completed | May 2013 | 48 |
| NCT01778049Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Mar 2015 | 708 |
How it is read
Names in the registry
- “BI 10773”, 71 entries
- “Empagliflozin”, 53 entries
- “BI10773”, 7 entries
- “Empagliflozin/Metformin”, 4 entries
- “Empagliflozin + Linagliptin”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 67 studies
- Heart Failure, 6 studies
- Diabetes Mellitus, Type 1, 5 studies
- Renal Insufficiency, Chronic, 4 studies
- Diabetes Mellitus, Lipoatrophic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.